The last time I wrote about Verastem, Inc. (VSTM) it was in a Seeking Alpha article entitled "Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination." With respect to this article ...
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed ...
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer ...
BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback